VCAM1 from Glial Cells Enhances the Advancement of Gliomas
-
By
-
Jiajing Dai
-
Hailong Zheng
-
Jiaxu Luo
-
Minlin Dai
-
Xiao-Ling Hu
-
Wenzhi Sun
-
April 24, 2026
-
Clinical Scorecard: VCAM1 from Glial Cells Enhances the Advancement of Gliomas
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | VCAM1 mediates interactions between glioma cells and the tumor microenvironment, promoting tumor progression, particularly in low-grade gliomas. |
| Target Population | |
| Care Setting | |
Key Highlights
- VCAM1 is highly expressed in glioma stem cell-like cells (GSLCs).
- Selective deletion of astrocytic VCAM1 extends survival in glioma-bearing mice.
- Lower VCAM1 expression correlates with prolonged survival in low-grade glioma patients.
- VCAM1's role in glioblastoma remains less defined compared to low-grade gliomas.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Monitor VCAM1 expression changes during treatment to assess therapeutic response, especially in glioblastoma patients.
Risks
Patient & Prescribing Data
Patients diagnosed with gliomas, especially those with low-grade gliomas and glioblastoma.
Targeting VCAM1 may enhance treatment outcomes by disrupting tumor microenvironment interactions.
Clinical Best Practices
- Integrate VCAM1 expression analysis into routine glioma patient assessments, with a focus on both low-grade gliomas and glioblastoma.
References
